Optimal lipid-lowering therapy in patients who were functionally deferred percutaneous coronary intervention

Area of Science:

• Cardiology
• Interventional Cardiology

Background:

• Deferring percutaneous coronary intervention (PCI) for functionally insignificant coronary stenosis (Fractional Flow Reserve [FFR] > 0.80) is linked to positive long-term outcomes.
• The "lower-the-better" strategy for managing low-density lipoprotein cholesterol (LDL-C) is a recognized non-angioplasty approach to enhance clinical results in patients undergoing PCI.

Purpose of the Study:

• To investigate the optimal LDL-C management strategy for patients with intermediate coronary stenosis where PCI was deferred based on FFR values.
• To determine if LDL-C levels impact major adverse cardiovascular and cerebrovascular events (MACCE) in this specific patient group.

Main Methods:

• An observational study involving 273 patients with a single target vessel and deferred PCI (FFR > 0.80).
• Patients were stratified by FFR (0.81-0.85 vs. > 0.85) and LDL-C levels (< 100 mg/dL vs. ≥ 100 mg/dL).
• The primary endpoint was MACCE, encompassing death, myocardial infarction, stroke, heart failure hospitalization, and unplanned revascularization.

Main Results:

• Patients with FFR 0.81-0.85 exhibited a significantly higher MACCE rate compared to those with FFR > 0.85 (p=0.003).
• In the FFR 0.81-0.85 group, lower LDL-C (< 100 mg/dL) was associated with a significantly lower MACCE rate (p=0.006).
• No significant difference in MACCE rates was observed between LDL-C groups for patients with FFR > 0.85 (p=0.84).

Conclusions:

• Uncontrolled LDL-C levels correlate with increased MACCE risk in patients with deferred PCI due to FFR values of 0.81-0.85.
• This high-risk subgroup warrants aggressive LDL-C-lowering therapy to mitigate adverse cardiovascular outcomes.